SCLX Scilex Holding Co
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1820190 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-28.5%
TTM net income YoY-473.7%
TTM EPS YoY-2,120.1%
Revenue 3-yr CAGR-12.0%
Net income 3-yr CAGR—
Margins
Gross margin161.1%
Operating margin-1,136.4%
Net margin-1,469.8%
FCF margin—
EBITDA margin-1,119.8%
Returns
ROE—
ROA-275.4%
ROIC (approx.)—
Asset turnover0.19x
Leverage & solvency
Liabilities / assets222.5%
Debt / equity—
Current ratio0.07x
Interest coverage-22.20x
Cash quality & payout
Operating cash flow / net income0.04x
Accruals ratio-265.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $30.25M | $56.59M |
| Cost of revenue | $10.60M | $16.69M |
| Gross profit | $125.80M | $167.40M |
| R&D expense | $20.71M | $9.64M |
| SG&A expense | $266.88M | $119.02M |
| Operating income | -$346.01M | -$83.40M |
| Interest expense | $11.46M | $1.96M |
| Pretax income | -$374.03M | -$72.81M |
| Income tax | $26,000 | -$1,000 |
| Net income | -$374.05M | -$72.81M |
| EBITDA | -$341.38M | -$79.35M |
| EPS (basic) | -36.48 | -7.24 |
| EPS (diluted) | -36.48 | -8.05 |
| Weighted avg. shares (diluted) | 11,034 | 10,145 |
| Balance sheet | ||
| Cash & equivalents | $4.96M | $3.27M |
| Receivables | $15.24M | $26.44M |
| Inventory | $4.79M | $2.44M |
| Current assets | $38.36M | $41.55M |
| PP&E, net | $13.60M | $708,000 |
| Goodwill | $13.48M | $13.48M |
| Intangibles | $59.09M | $32.45M |
| Total assets | $364.98M | $92.95M |
| Current liabilities | $483.65M | $259.63M |
| Short-term debt | $83.26M | $34.88M |
| Total liabilities | $576.73M | $285.59M |
| Shareholders' equity | -$207.78M | -$192.64M |
| Shares outstanding | 7.03M | 5.24M |
| Cash flow statement | ||
| Operating cash flow | $3.82M | $19.35M |
| Capital expenditure | $133,000 | $0 |
| Free cash flow | $3.68M | $19.35M |
| Investing cash flow | $4.08M | -$2.67M |
| Financing cash flow | -$5.46M | -$18.13M |
| Depreciation & amortization | $4.62M | $4.05M |
| Stock-based compensation | $15.49M | $15.69M |
| Dividends paid | — | $8.65M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.